The increasing popularity of biosimilars in treating diseases, such as cancer, autoimmune diseases, blood disorders, and others, and the low cost of biosimilars as compared to biologics are some of the major factors driving the market.
Highlights
The global Biosimilar Contract Manufacturing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Biosimilar Contract Manufacturing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Biosimilar Contract Manufacturing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Biosimilar Contract Manufacturing in Oncology is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Biosimilar Contract Manufacturing include Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., Biocon, IQVIA Inc., AGC Biologics, Samsung Biologics, WuXi Biologics and Element Materials Technology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Contract Manufacturing.
The Biosimilar Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar Contract Manufacturing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Boehringer Ingelheim Biopharmaceuticals GmbH
Lonza
Catalent, Inc.
Biocon
IQVIA Inc.
AGC Biologics
Samsung Biologics
WuXi Biologics
Element Materials Technology
Rentschler Biopharma SE
Avid Bioservices, Inc.
Alcami Corporation, Inc.
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Thermo Fisher Scientific Inc.
Almac Group
Segment by Type
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic & Autoimmune Disorders
Rheumatoid Arthritis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Contract Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Contract Manufacturing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Recombinant Non-glycosylated Proteins
1.2.3 Recombinant Glycosylated Proteins
1.3 Market by Application
1.3.1 Global Biosimilar Contract Manufacturing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Growth Hormonal Deficiency
1.3.5 Chronic & Autoimmune Disorders
1.3.6 Rheumatoid Arthritis
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Contract Manufacturing Market Perspective (2018-2029)
2.2 Biosimilar Contract Manufacturing Growth Trends by Region
2.2.1 Global Biosimilar Contract Manufacturing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilar Contract Manufacturing Historic Market Size by Region (2018-2023)
2.2.3 Biosimilar Contract Manufacturing Forecasted Market Size by Region (2024-2029)
2.3 Biosimilar Contract Manufacturing Market Dynamics
2.3.1 Biosimilar Contract Manufacturing Industry Trends
2.3.2 Biosimilar Contract Manufacturing Market Drivers
2.3.3 Biosimilar Contract Manufacturing Market Challenges
2.3.4 Biosimilar Contract Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Contract Manufacturing Players by Revenue
3.1.1 Global Top Biosimilar Contract Manufacturing Players by Revenue (2018-2023)
3.1.2 Global Biosimilar Contract Manufacturing Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilar Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Contract Manufacturing Revenue
3.4 Global Biosimilar Contract Manufacturing Market Concentration Ratio
3.4.1 Global Biosimilar Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Contract Manufacturing Revenue in 2022
3.5 Biosimilar Contract Manufacturing Key Players Head office and Area Served
3.6 Key Players Biosimilar Contract Manufacturing Product Solution and Service
3.7 Date of Enter into Biosimilar Contract Manufacturing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Contract Manufacturing Breakdown Data by Type
4.1 Global Biosimilar Contract Manufacturing Historic Market Size by Type (2018-2023)
4.2 Global Biosimilar Contract Manufacturing Forecasted Market Size by Type (2024-2029)
5 Biosimilar Contract Manufacturing Breakdown Data by Application
5.1 Global Biosimilar Contract Manufacturing Historic Market Size by Application (2018-2023)
5.2 Global Biosimilar Contract Manufacturing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biosimilar Contract Manufacturing Market Size (2018-2029)
6.2 North America Biosimilar Contract Manufacturing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biosimilar Contract Manufacturing Market Size by Country (2018-2023)
6.4 North America Biosimilar Contract Manufacturing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Contract Manufacturing Market Size (2018-2029)
7.2 Europe Biosimilar Contract Manufacturing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biosimilar Contract Manufacturing Market Size by Country (2018-2023)
7.4 Europe Biosimilar Contract Manufacturing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Contract Manufacturing Market Size (2018-2029)
8.2 Asia-Pacific Biosimilar Contract Manufacturing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biosimilar Contract Manufacturing Market Size by Region (2018-2023)
8.4 Asia-Pacific Biosimilar Contract Manufacturing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar Contract Manufacturing Market Size (2018-2029)
9.2 Latin America Biosimilar Contract Manufacturing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biosimilar Contract Manufacturing Market Size by Country (2018-2023)
9.4 Latin America Biosimilar Contract Manufacturing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Contract Manufacturing Market Size (2018-2029)
10.2 Middle East & Africa Biosimilar Contract Manufacturing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biosimilar Contract Manufacturing Market Size by Country (2018-2023)
10.4 Middle East & Africa Biosimilar Contract Manufacturing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim Biopharmaceuticals GmbH
11.1.1 Boehringer Ingelheim Biopharmaceuticals GmbH Company Detail
11.1.2 Boehringer Ingelheim Biopharmaceuticals GmbH Business Overview
11.1.3 Boehringer Ingelheim Biopharmaceuticals GmbH Biosimilar Contract Manufacturing Introduction
11.1.4 Boehringer Ingelheim Biopharmaceuticals GmbH Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.1.5 Boehringer Ingelheim Biopharmaceuticals GmbH Recent Development
11.2 Lonza
11.2.1 Lonza Company Detail
11.2.2 Lonza Business Overview
11.2.3 Lonza Biosimilar Contract Manufacturing Introduction
11.2.4 Lonza Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.2.5 Lonza Recent Development
11.3 Catalent, Inc.
11.3.1 Catalent, Inc. Company Detail
11.3.2 Catalent, Inc. Business Overview
11.3.3 Catalent, Inc. Biosimilar Contract Manufacturing Introduction
11.3.4 Catalent, Inc. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.3.5 Catalent, Inc. Recent Development
11.4 Biocon
11.4.1 Biocon Company Detail
11.4.2 Biocon Business Overview
11.4.3 Biocon Biosimilar Contract Manufacturing Introduction
11.4.4 Biocon Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.4.5 Biocon Recent Development
11.5 IQVIA Inc.
11.5.1 IQVIA Inc. Company Detail
11.5.2 IQVIA Inc. Business Overview
11.5.3 IQVIA Inc. Biosimilar Contract Manufacturing Introduction
11.5.4 IQVIA Inc. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.5.5 IQVIA Inc. Recent Development
11.6 AGC Biologics
11.6.1 AGC Biologics Company Detail
11.6.2 AGC Biologics Business Overview
11.6.3 AGC Biologics Biosimilar Contract Manufacturing Introduction
11.6.4 AGC Biologics Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.6.5 AGC Biologics Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Detail
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Biosimilar Contract Manufacturing Introduction
11.7.4 Samsung Biologics Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.7.5 Samsung Biologics Recent Development
11.8 WuXi Biologics
11.8.1 WuXi Biologics Company Detail
11.8.2 WuXi Biologics Business Overview
11.8.3 WuXi Biologics Biosimilar Contract Manufacturing Introduction
11.8.4 WuXi Biologics Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.8.5 WuXi Biologics Recent Development
11.9 Element Materials Technology
11.9.1 Element Materials Technology Company Detail
11.9.2 Element Materials Technology Business Overview
11.9.3 Element Materials Technology Biosimilar Contract Manufacturing Introduction
11.9.4 Element Materials Technology Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.9.5 Element Materials Technology Recent Development
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Detail
11.10.2 Rentschler Biopharma SE Business Overview
11.10.3 Rentschler Biopharma SE Biosimilar Contract Manufacturing Introduction
11.10.4 Rentschler Biopharma SE Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.10.5 Rentschler Biopharma SE Recent Development
11.11 Avid Bioservices, Inc.
11.11.1 Avid Bioservices, Inc. Company Detail
11.11.2 Avid Bioservices, Inc. Business Overview
11.11.3 Avid Bioservices, Inc. Biosimilar Contract Manufacturing Introduction
11.11.4 Avid Bioservices, Inc. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.11.5 Avid Bioservices, Inc. Recent Development
11.12 Alcami Corporation, Inc.
11.12.1 Alcami Corporation, Inc. Company Detail
11.12.2 Alcami Corporation, Inc. Business Overview
11.12.3 Alcami Corporation, Inc. Biosimilar Contract Manufacturing Introduction
11.12.4 Alcami Corporation, Inc. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.12.5 Alcami Corporation, Inc. Recent Development
11.13 Fujifilm Kyowa Kirin Biologics Co., Ltd.
11.13.1 Fujifilm Kyowa Kirin Biologics Co., Ltd. Company Detail
11.13.2 Fujifilm Kyowa Kirin Biologics Co., Ltd. Business Overview
11.13.3 Fujifilm Kyowa Kirin Biologics Co., Ltd. Biosimilar Contract Manufacturing Introduction
11.13.4 Fujifilm Kyowa Kirin Biologics Co., Ltd. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.13.5 Fujifilm Kyowa Kirin Biologics Co., Ltd. Recent Development
11.14 Thermo Fisher Scientific Inc.
11.14.1 Thermo Fisher Scientific Inc. Company Detail
11.14.2 Thermo Fisher Scientific Inc. Business Overview
11.14.3 Thermo Fisher Scientific Inc. Biosimilar Contract Manufacturing Introduction
11.14.4 Thermo Fisher Scientific Inc. Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.14.5 Thermo Fisher Scientific Inc. Recent Development
11.15 Almac Group
11.15.1 Almac Group Company Detail
11.15.2 Almac Group Business Overview
11.15.3 Almac Group Biosimilar Contract Manufacturing Introduction
11.15.4 Almac Group Revenue in Biosimilar Contract Manufacturing Business (2018-2023)
11.15.5 Almac Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Boehringer Ingelheim Biopharmaceuticals GmbH
Lonza
Catalent, Inc.
Biocon
IQVIA Inc.
AGC Biologics
Samsung Biologics
WuXi Biologics
Element Materials Technology
Rentschler Biopharma SE
Avid Bioservices, Inc.
Alcami Corporation, Inc.
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Thermo Fisher Scientific Inc.
Almac Group
*If Applicable.